LOW-DOSE INTERLEUKIN-2 (IL-2) EXPANDS NATURAL-KILLER (NK) CELL-POPULATIONS IN-VIVO BY SELECTIVE PREVENTION OF APOPTOSIS

被引：0
|
作者：
BLUMAN, EM
LINDEMANN, MJ
PORTER, MM
PIXLEY, L
FRANKEL, SR
CALIGIURI, MA
机构：
[1] ROSWELL PK CANC INST,DEPT MED,BUFFALO,NY
[2] ROSWELL PK CANC INST,DEPT MOLEC MED,BUFFALO,NY
[3] ROSWELL PK CANC INST,DEPT MOLEC IMMUNOL,BUFFALO,NY
来源：
BLOOD | 1994年 / 84卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A288 / A288
页数：1
相关论文
共 50 条
  • [31] THE ROLE OF INTERLEUKIN-2 IN HUMAN NATURAL-KILLER CELL-PROLIFERATION
    LONDON, L
    PERUSSIA, B
    TRINCHIERI, G
    FEDERATION PROCEEDINGS, 1986, 45 (03) : 634 - 634
  • [32] A SYNTHETIC PEPTIDE OF C-REACTIVE PROTEIN (CRP) COMBINED WITH INTERLEUKIN-2 (IL-2) AUGMENTS HUMAN MONOCYTE BUT NOT NATURAL-KILLER (NK) CYTOLYTIC ACTIVITY
    BARNA, BP
    THOMASSEN, MJ
    EPPSTEIN, D
    JACOBS, B
    DEODHAR, SD
    FASEB JOURNAL, 1992, 6 (04): : A1433 - A1433
  • [33] A COMPARATIVE-ANALYSIS OF NATURAL-KILLER (NK) ACTIVITY, INTERLEUKIN-2 (IL-2), INTERFERON (IFN) PRODUCTION AND LYMPHOCYTE SUBPOPULATIONS IN CORD AND ADULT-BLOOD
    HICKS, MJ
    KIBLER, R
    WRIGHT, A
    TAUSSIG, L
    LABORATORY INVESTIGATION, 1986, 54 (01) : A25 - A25
  • [34] Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing
    Meropol, NJ
    Barresi, GM
    Fehniger, TA
    Hitt, J
    Franklin, M
    Caligiuri, MA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 46 (06) : 318 - 326
  • [35] Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing
    Meropol N.J.
    Barresi G.M.
    Fehniger T.A.
    Hitt J.
    Franklin M.
    Caligiuri M.A.
    Cancer Immunology, Immunotherapy, 1998, 46 (6) : 318 - 326
  • [36] NATURAL-KILLER-CELLS (NK) AND INTERLEUKIN 2 (IL-2) IN CROHNS-DISEASE
    POLO, JLL
    VIERNA, SE
    MORENCOS, FC
    CASTANO, FL
    ROMERO, FP
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 1990, 78 (02) : 71 - 75
  • [37] ADDITION OF INTERLEUKIN-12 TO LOW-DOSE INTERLEUKIN-2 TREATMENT IMPROVES ANTITUMOR EFFICACY IN-VIVO
    LEDER, GH
    OPPENHEIM, M
    ROSENSTEIN, M
    LOTZE, MT
    BERGER, HG
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1995, 33 (09): : 499 - 502
  • [38] A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
    Garcia, J. A.
    Rini, B. I.
    Mekhail, T.
    Triozzi, P.
    Elson, P.
    Nemec, C.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] GENERATION OF MOUSE NATURAL-KILLER (NK) CELL-ACTIVITY - EFFECT OF INTERLEUKIN-2 (IL-2) AND INTERFERON (IFN) ON THE INVIVO DEVELOPMENT OF NATURAL-KILLER-CELLS FROM BONE-MARROW (BM) PROGENITOR CELLS
    RICCARDI, C
    GIAMPIETRI, A
    MIGLIORATI, G
    CANNARILE, L
    DADAMIO, L
    HERBERMAN, RB
    INTERNATIONAL JOURNAL OF CANCER, 1986, 38 (04) : 553 - 562
  • [40] ENHANCEMENT OF MATERNAL AND NEONATAL NATURAL-KILLER CELL-ACTIVITY WITH INTERLEUKIN-2
    BAKER, DA
    MILCH, PO
    SALVATORE, W
    LUFT, B
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 157 (03) : 780 - 781
12345